151 related articles for article (PubMed ID: 2908815)
1. Human vasodilator responses to a dopamine agonist: possible mechanisms.
Redman D; Thom SA; Hughes AD; Hasan S; Sever PS
J Hypertens Suppl; 1985 Dec; 3(3):S177-8. PubMed ID: 2908815
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of a specific dopaminergic receptor agonist with metoclopramide in horses.
Eades SC; Moore JN
Am J Vet Res; 1993 Jan; 54(1):122-5. PubMed ID: 8093992
[TBL] [Abstract][Full Text] [Related]
3. Effects of dopamine DA1-receptor blockade and angiotensin converting enzyme inhibition on the renal actions of fenoldopam in the anaesthetized dog.
Clark KL; Hilditch A; Robertson MJ; Drew GM
J Hypertens; 1991 Dec; 9(12):1143-50. PubMed ID: 1685741
[TBL] [Abstract][Full Text] [Related]
4. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat.
Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I
J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375
[TBL] [Abstract][Full Text] [Related]
5. Effects of fenoldopam on cecal blood flow and mechanical activity in horses.
Clark ES; Moore JN
Am J Vet Res; 1989 Nov; 50(11):1926-30. PubMed ID: 2575878
[TBL] [Abstract][Full Text] [Related]
6. Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study.
Hadengue A; Moreau R; Bacq Y; Gaudin C; Braillon A; Lebrec D
Hepatology; 1991 Jan; 13(1):111-6. PubMed ID: 1671029
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
Zhao RR; Wang PH; Zhang WF; Fennell WH
Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
[TBL] [Abstract][Full Text] [Related]
8. Evidence from functional and autoradiographic studies for the presence of tubular dopamine-1 receptors and their involvement in the renal effects of fenoldopam.
Hedge SS; Ricci A; Amenta F; Lokhandwala MF
J Pharmacol Exp Ther; 1989 Dec; 251(3):1237-45. PubMed ID: 2574743
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular responses in healthy subjects to a novel oral dopamine agonist, fenoldopam.
Cregeen RJ; Rudge PJ; Mills JG; Vincent SH; Burland WL
J Hypertens Suppl; 1985 Dec; 3(3):S173-5. PubMed ID: 2908814
[TBL] [Abstract][Full Text] [Related]
10. Fenoldopam is a partial agonist at dopamine-1 (DA1) receptors in LLC-PK1 cells.
Grenader A; Healy DP
J Pharmacol Exp Ther; 1991 Jul; 258(1):193-8. PubMed ID: 1677038
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and renal hemodynamic effects of A-68930 in the conscious dog: a comparison with fenoldopam.
Christie MI; Smith GW
J Pharmacol Exp Ther; 1994 Feb; 268(2):565-70. PubMed ID: 7906731
[TBL] [Abstract][Full Text] [Related]
12. Intrarenally produced angiotensin II opposes the natriuretic action of the dopamine-1 receptor agonist fenoldopam in rats.
Chen CJ; Apparsundaram S; Lokhandwala MF
J Pharmacol Exp Ther; 1991 Feb; 256(2):486-91. PubMed ID: 1671595
[TBL] [Abstract][Full Text] [Related]
13. Functional ontogeny of pulmonary vascular DA1 dopamine receptors in the isolated perfused rabbit lung.
Polak MJ; Taylor DA
Pediatr Res; 1994 Feb; 35(2):228-32. PubMed ID: 7909367
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dopamine and fenoldopam effects on renal blood flow and prostacyclin excretion in normal and essential hypertensive subjects.
Bughi S; Horton R; Antonipillai I; Manoogian C; Ehrlich L; Nadler J
J Clin Endocrinol Metab; 1989 Dec; 69(6):1116-21. PubMed ID: 2573613
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
Kinter LB; Horner E; Mann WA; Weinstock J; Ruffolo RR
Chirality; 1990; 2(4):219-25. PubMed ID: 1982058
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology of fenoldopam.
Nichols AJ; Ruffolo RR; Brooks DP
Am J Hypertens; 1990 Jun; 3(6 Pt 2):116S-119S. PubMed ID: 1974439
[TBL] [Abstract][Full Text] [Related]
17. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog.
Nichols AJ; Koster PF; Brooks DP; Ruffolo RR
J Pharmacol Exp Ther; 1992 Jan; 260(1):269-74. PubMed ID: 1346161
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model.
Vanmolkot FH; Van der Schueren BJ; de Hoon JN
Clin Pharmacol Ther; 2006 Mar; 79(3):263-73. PubMed ID: 16513450
[TBL] [Abstract][Full Text] [Related]
19. 5-Hydroxytryptamine receptor activity of the dopamine receptor agonist fenoldopam in canine tracheal smooth muscle.
Gretler DD; Jones KC; Murphy MB
J Pharmacol Exp Ther; 1992 Feb; 260(2):491-8. PubMed ID: 1346635
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man.
Bakris GL; Weber RR; Nelson K; Elliott WJ; Kaplan E; Murphy MB
Miner Electrolyte Metab; 1988; 14(6):343-6. PubMed ID: 2906737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]